$1.77 Billion is the total value of QVT Financial LP's 61 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 137.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | Buy | SPDR SERIES TRUSTs&p biotech | $28,649,000 | +694.3% | 337,567 | +710.2% | 1.62% | +1106.7% |
| TWX | Buy | TIME WARNER INC | $20,877,000 | +35.5% | 228,244 | +51.8% | 1.18% | +105.2% |
| SBGI | Buy | SINCLAIR BROADCAST GROUP INCcl a | $10,412,000 | +72.0% | 275,097 | +45.7% | 0.59% | +161.3% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $8,615,000 | +71.6% | 1,124,295 | +70.1% | 0.49% | +159.9% |
| NAT | Buy | NORDIC AMERICAN TANKERS LIMI | $8,547,000 | +540.2% | 3,703,929 | +1381.6% | 0.48% | +864.0% |
| QRVO | New | QORVO INC | $6,993,000 | – | 105,000 | +100.0% | 0.40% | – |
| PTEN | Buy | PATTERSON UTI ENERGY INC | $6,698,000 | +97.8% | 291,100 | +80.0% | 0.38% | +200.0% |
| New | JEFFERIES GROUP INC NEWdbcv 3.875%11/0 | $6,543,000 | – | 6,500,000 | +100.0% | 0.37% | – | |
| New | INTEL CORPsdcv 3.250% 8/0 | $6,471,000 | – | 2,895,000 | +100.0% | 0.36% | – | |
| FRAC | Buy | KEANE GROUP INC | $6,462,000 | +105.1% | 339,922 | +80.0% | 0.36% | +212.0% |
| BABA | New | ALIBABA GROUP HLDG LTDsponsored ads | $5,087,000 | – | 29,500 | +100.0% | 0.29% | – |
| HIMX | New | HIMAX TECHNOLOGIES INCsponsored adr | $5,038,000 | – | 483,500 | +100.0% | 0.28% | – |
| CTRP | New | CTRIP COM INTL LTD | $4,997,000 | – | 113,300 | +100.0% | 0.28% | – |
| GNRT | New | GENER8 MARITIME INC | $4,375,000 | – | 660,940 | +100.0% | 0.25% | – |
| EQT | New | EQT CORP | $3,889,000 | – | 68,323 | +100.0% | 0.22% | – |
| TRCO | New | TRIBUNE MEDIA COcl a | $3,208,000 | – | 75,544 | +100.0% | 0.18% | – |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $1,420,000 | -4.0% | 15,923 | +0.2% | 0.08% | +45.5% |
| GLF | New | GULFMARK OFFSHORE INC | $615,000 | – | 26,980 | +100.0% | 0.04% | – |
| RDFN | New | REDFIN CORP | $250,000 | – | 7,970 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MAKEMYTRIP LIMITED MAURITIUS | 38 | Q3 2023 | 6.2% |
| NEW YORK TIMES CO | 34 | Q3 2023 | 2.6% |
| ACCELERON PHARMA INC | 32 | Q3 2021 | 2.8% |
| JPMORGAN CHASE & CO | 32 | Q3 2021 | 2.2% |
| SAREPTA THERAPEUTICS INC | 32 | Q3 2023 | 1.1% |
| BIOMARIN PHARMACEUTICAL INC | 32 | Q3 2023 | 0.5% |
| GOLDMAN SACHS GROUP INC | 30 | Q3 2023 | 5.4% |
| ACADIA PHARMACEUTICALS INC | 28 | Q3 2023 | 0.2% |
| WELLS FARGO CO NEW | 27 | Q4 2020 | 1.5% |
| NEXSTAR MEDIA GROUP INC | 26 | Q3 2023 | 3.4% |
View QVT Financial LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| MP Materials Corp. / DE | May 18, 2023 | 8,853,712 | 5.0% |
| Grindrod Shipping Holdings Ltd.Sold out | February 14, 2022 | 0 | 0.0% |
| AEHR TEST SYSTEMSSold out | February 14, 2020 | 0 | 0.0% |
| Arbutus Biopharma CorpSold out | July 12, 2019 | 0 | 0.0% |
| Axovant Gene Therapies Ltd.Sold out | July 12, 2019 | 0 | 0.0% |
| Myovant Sciences Ltd.Sold out | July 12, 2019 | 0 | 0.0% |
| Urovant Sciences Ltd.Sold out | July 12, 2019 | 0 | 0.0% |
| Axovant Sciences Ltd. | March 19, 2019 | 105,952,381 | 58.2% |
| Hunter Maritime Acquisition Corp.Sold out | February 14, 2019 | 0 | 0.0% |
| AGENUS INC | February 14, 2018 | 3,201,263 | 3.2% |
View QVT Financial LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-03-07 |
| SC 13G/A | 2024-03-07 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-10-02 |
| 144 | 2023-09-28 |
| 13F-HR | 2023-08-14 |
| SC 13D/A | 2023-05-18 |
View QVT Financial LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.